Page 5 - கைலி ஓக்கீபே News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from கைலி ஓக்கீபே. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In கைலி ஓக்கீபே Today - Breaking & Trending Today

PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar

PTC Therapeutics to Host PTC518 Huntington Disease Deep Dive Webinar
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) will host a webinar in its deep dive series discussing the PTC518 Huntington disease (HD) program on Thursday, April 15 at 9 a.m. E.T.
The Huntington Disease Deep Dive will provide an overview of PTC s splicing platform and the identification of molecules that have selectivity and specificity. PTC will highlight its Huntington program and the potential advantages of an orally bioavailable compound. PTC will discuss in detail the splicing modifier, PTC518, that is in an ongoing Phase 1 clinical trial. In preclinical studies, PTC518 has demonstrated broad biodistribution that uniformly reaches all regions of the brain and periphery and has shown reduction in Huntingtin protein (HTT) levels with a 1:1 correlation between blood and brain. PTC will als ....

United States , Kylie Okeefe , Jane Baj , Therapeutics Inc , Huntington Disease Deep Dive , More Information , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Retrieved April , ஒன்றுபட்டது மாநிலங்களில் , கைலி ஓக்கீபே , ஜேன் பஜ் , சிகிச்சை இன்க் , ஹண்டிங்டன் நோய் ஆழமான டைவ் , மேலும் தகவல் , பார்க்கிறது அறிக்கைகள் , ப்ரைவேட் பத்திரங்கள் வழக்கு சீர்திருத்தம் நாடகம் , ஆண்டு அறிக்கை ,

PTC Therapeutics Received Gallup's "Don Clifton Strengths-Based Culture" Award

Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 Don Clifton Strengths-Based Culture Award from Gallup. The award recognizes organizations with strong workplace cultures that get the best out of their employees by focusing and developing their strengths and placing them at the center of how they work every day.
We are honored to accept this award and appreciate the recognition that at PTC we have built an engaging and innovative work environment that is collaborative and committed to develop our employees, said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. While the past year has presented many challenges due to the COVID-19 pandemic, our team has proven that we can work smarter and go farther together. At PTC we say that science is our foundation, and our culture is our heart. ....

United States , Kylie Okeefe , Stuartw Peltz , Clifton Strengthsfinder , Jane Baj , Don Clifton , Therapeutics Inc , University Of Nebraska , Clifton Strengths Based Culture , Chief Executive Officer , Don Clifton Strengths Based Culture Award , Clifton Strengths Based , Clifton Strengths Based Culture Award , More Information , ஒன்றுபட்டது மாநிலங்களில் , கைலி ஓக்கீபே , ஜேன் பஜ் , தாதா கிளிப்டன் , சிகிச்சை இன்க் , பல்கலைக்கழகம் ஆஃப் நெப்ராஸ்கா , கிளிப்டன் பலங்கள் அடிப்படையிலானது கலாச்சாரம் , தலைமை நிர்வாகி அதிகாரி , தாதா கிளிப்டன் பலங்கள் அடிப்படையிலானது கலாச்சாரம் விருது , கிளிப்டன் பலங்கள் அடிப்படையிலானது , கிளிப்டன் பலங்கள் அடிப்படையிலானது கலாச்சாரம் விருது , மேலும் தகவல் ,

PTC Therapeutics Received Gallup's Don Clifton Strengths-Based Culture Award

Published: Apr 07, 2021

SOUTH PLAINFIELD, N.J., April 7, 2021 /PRNewswire/ PTC Therapeutics, Inc.. (NASDAQ: PTCT) today announced that it has been named a winner of the 2021 Don Clifton Strengths-Based Culture Award from Gallup. The award recognizes organizations with strong workplace cultures that get the best out of their employees by focusing and developing their strengths and placing them at the center of how they work every day.
We are honored to accept this award and appreciate the recognition that at PTC we have built an engaging and innovative work environment that is collaborative and committed to develop our employees, said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. While the past year has presented many challenges due to the COVID-19 pandemic, our team has proven that we can work smarter and go farther together. At PTC we say that science is our foundation, and our culture is our heart. ....

United States , Kylie Okeefe , Stuartw Peltz , Clifton Strengthsfinder , Jane Baj , Don Clifton , Therapeutics Inc , University Of Nebraska , Clifton Strengths Based Culture , Chief Executive Officer , Don Clifton Strengths Based Culture Award , Clifton Strengths Based , Clifton Strengths Based Culture Award , More Information , ஒன்றுபட்டது மாநிலங்களில் , கைலி ஓக்கீபே , ஜேன் பஜ் , தாதா கிளிப்டன் , சிகிச்சை இன்க் , பல்கலைக்கழகம் ஆஃப் நெப்ராஸ்கா , கிளிப்டன் பலங்கள் அடிப்படையிலானது கலாச்சாரம் , தலைமை நிர்வாகி அதிகாரி , தாதா கிளிப்டன் பலங்கள் அடிப்படையிலானது கலாச்சாரம் விருது , கிளிப்டன் பலங்கள் அடிப்படையிலானது , கிளிப்டன் பலங்கள் அடிப்படையிலானது கலாச்சாரம் விருது , மேலும் தகவல் ,

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™

PTC Therapeutics Announces Commercial Milestone Payment Following the Recent European Approval of Evrysdi™
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., April 1, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that a $20 million milestone payment was triggered by the first commercial sale of Evrysdi™ (risdiplam) in the European Union under its License and Collaboration Agreement with Roche. Approval for Evrysdi from the European Medicines Agency was received on March 30 for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months and older.
We are happy to see the rapid adoption of Evrysdi in the EU which speaks to the need for new treatments for SMA patients, said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. We are delighted that an effective at-home therapy will be available to SMA patients. We recognize that a large proportion of SMA patients in ....

United States , Kylie Okeefe , Stuartw Peltz , Jane Baj , Toddler Development , Drug Administration , Therapeutics Inc , European Union , Roche Group , European Medicines Agency , Health Authority , Collaboration Agreement , Chief Executive Officer , Temporary Authorization , Spinal Muscular Atrophy , Gross Motor Scale , Bayley Scales , Motor Function Measure , More Information , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Ptc Therapeutics , Health Care Amp Hospitals , Medical Pharmaceuticals , ஒன்றுபட்டது மாநிலங்களில் ,

Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients

Results from the Second Year of Evrysdi™ (risdiplam) Treatment Demonstrated Sustained Improvement of Motor Function in a Broad Range of SMA Patients
- Sustained or improved motor function was observed with 24 months of treatment -
- Patients and caregivers reported a greater ability to complete activities of daily livingwith increased independence -
News provided by
Share this article
Share this article
SOUTH PLAINFIELD, N.J., March 16, 2021 /PRNewswire/ PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced two-year data from Part 2 of the SUNFISH trial evaluating Evrysdi™ (risdiplam) in children and adults with Type 2 or Type 3 spinal muscular atrophy (SMA) at the 2021 Muscular Dystrophy Association (MDA) Virtual and Scientific Conference. These results demonstrated that Evrysdi patients sustained or improved in motor function after 24 months of treatment. Furthermore, the patients and caregivers reported improvements in their ability to function i ....

United States , Kylie Okeefe , Stuartw Peltz , Jane Baj , Muscular Dystrophy Association , Toddler Development , Drug Administration , Therapeutics Inc , Roche Group , Dystrophy Association , Chief Executive Officer , Motor Function Measure , Revised Upper Limb Module , Hammersmith Functional Motor Scale Expanded , Evrysdi Clinical , Gross Motor Scale , Bayley Scales , Spinal Muscular Atrophy , More Information , Looking Statements , Private Securities Litigation Reform Act , Annual Report , Ptc Therapeutics , ஒன்றுபட்டது மாநிலங்களில் , கைலி ஓக்கீபே , ஜேன் பஜ் ,